Drug Profile
Research programme: serotonin 2B receptor antagonists - Biofrontera AG
Latest Information Update: 29 Sep 2009
Price :
$50
*
At a glance
- Originator Biofrontera AG
- Class
- Mechanism of Action Serotonin 2B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Migraine; Pulmonary hypertension
Most Recent Events
- 29 Sep 2009 No development reported - Preclinical for Migraine in Germany (unspecified route)
- 29 Sep 2009 No development reported - Preclinical for Pulmonary hypertension in Germany (unspecified route)
- 15 Mar 2007 This programme is still in active development